Charles Ricordel1, Alexandra Lespagnol2, Francisco Llamas-Gutierrez3, Marie de Tayrac2, Mallorie Kerjouan4, Alice Fievet2, Houda Hamdi-Rozé2, Amyrat Aliouat2, Benoit Desrues5, Jean Mosser6, Hervé Léna5. 1. Department of Respiratory Medicine, Pontchaillou Hospital, Rennes 1 University, Rennes, France; Chemistry, Oncogenesis, and Stress Signaling, INSERM U1242, Centre Eugène Marquis, Rennes, France. Electronic address: charles.ricordel@chu-rennes.fr. 2. Department of Molecular Genetics and Genomics, Pontchaillou Hospital, Rennes 1 University, Rennes, France. 3. Department of Pathology, Pontchaillou Hospital, Rennes 1 University, Rennes, France. 4. Department of Respiratory Medicine, Pontchaillou Hospital, Rennes 1 University, Rennes, France. 5. Department of Respiratory Medicine, Pontchaillou Hospital, Rennes 1 University, Rennes, France; Chemistry, Oncogenesis, and Stress Signaling, INSERM U1242, Centre Eugène Marquis, Rennes, France. 6. Department of Molecular Genetics and Genomics, Pontchaillou Hospital, Rennes 1 University, Rennes, France; Functional Integrated Genomics & Biomarkers, IGDR, UMR6290, CNRS, Rennes 1 University, Rennes, France.
Abstract
BACKGROUND: Lung cancer represents the leading cause of cancer-related death worldwide. Despite great advances in lung cancer management with the recent emergence of molecular targeted therapies for non-squamous non-small-cell lung cancer, no dramatic improvements have been achieved in lung squamous cell carcinoma (SCC). Mutations in discoidin domain receptor 2 (DDR2) gene were recently identified as promising molecular targets in this histology. The aim of this study is to describe the DDR2 mutational landscape of lung SCC and investigate the associated clinical factors. METHODS: Next-generation sequencing of the DDR2 gene was performed on 271 samples of lung SCC. Patients followed in our institution from January 2011 to August 2014 were retrospectively selected for data collection. Other driver gene alterations (EGFR, KRAS, BRAF, HER2, and PI3KCA) were analyzed using pyrosequencing. RESULTS: A total of 11 patients harboring a DDR2 mutation was detected among the 271 sequenced lung SCC samples (4%). We describe 10 unreported mutations, comprising a novel DDR2 exon 7 splice mutant. DDR2 mutations were not mutually exclusive with other driver gene alterations. One hundred thirty-six patients were included for clinical comparison and logistic regression analysis. No difference was detected between DDR2-mutant and DDR2 wild-type lung SCC regarding clinical characteristics or survival. CONCLUSION: DDR2 mutations were observed in 4% of cases of lung SCC of European descent. DDR2-mutated tumors can exhibit other driver gene alterations. No clinical characteristics were significantly associated with DDR2 mutation.
BACKGROUND:Lung cancer represents the leading cause of cancer-related death worldwide. Despite great advances in lung cancer management with the recent emergence of molecular targeted therapies for non-squamous non-small-cell lung cancer, no dramatic improvements have been achieved in lung squamous cell carcinoma (SCC). Mutations in discoidin domain receptor 2 (DDR2) gene were recently identified as promising molecular targets in this histology. The aim of this study is to describe the DDR2 mutational landscape of lung SCC and investigate the associated clinical factors. METHODS: Next-generation sequencing of the DDR2 gene was performed on 271 samples of lung SCC. Patients followed in our institution from January 2011 to August 2014 were retrospectively selected for data collection. Other driver gene alterations (EGFR, KRAS, BRAF, HER2, and PI3KCA) were analyzed using pyrosequencing. RESULTS: A total of 11 patients harboring a DDR2 mutation was detected among the 271 sequenced lung SCC samples (4%). We describe 10 unreported mutations, comprising a novel DDR2 exon 7 splice mutant. DDR2 mutations were not mutually exclusive with other driver gene alterations. One hundred thirty-six patients were included for clinical comparison and logistic regression analysis. No difference was detected between DDR2-mutant and DDR2 wild-type lung SCC regarding clinical characteristics or survival. CONCLUSION:DDR2 mutations were observed in 4% of cases of lung SCC of European descent. DDR2-mutated tumors can exhibit other driver gene alterations. No clinical characteristics were significantly associated with DDR2 mutation.